December 19, 2024
1 min watch
Save
VIDEO: Givosarin prevents attacks of acute intermittent porphyria
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Amy Dickey, MD, MSc, discusses an educational session she presented at ASH Annual Meeting that examined the use of givosarin for patients with acute intermittent porphyria.
In her session, Dickey, an assistant professor at Massachusetts General Hospital, looked at a form of porphyria that causes abdominal pain and neurologic issues.
“This medication givosarin [Givlaari, Alnylam Pharmaceuticals] actually inhibits one of the first steps of heme synthesis in the liver and prevents attacks. It's been very effective in our patients, and it was really great to be able to give an educational session about that,” Dickey said.
Reference:
- Dickey A, et al. Integrating new therapies into the management of classical heme diorders. Presented at: ASH Annual Meeting and Exposition; Dec. 7-10, 2024; San Diego.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Dickey reports receiving research funding from Alnylam Pharmaceuticals and Mitsubishi Tanabe, and consulting for Recordati Pharmaceuticals.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.